Streamex (STEX)
Market Price (12/4/2025): $4.61 | Market Cap: $79.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Streamex (STEX)
Market Price (12/4/2025): $4.61Market Cap: $79.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 122% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -31523% |
| Megatrend and thematic driversMegatrends include Digital Content & Streaming. Themes include Video Streaming, and Music Streaming. | Expensive valuation multiplesP/SPrice/Sales ratio is 2471x | |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.2% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -11895%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -11895% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 122% |
| Megatrend and thematic driversMegatrends include Digital Content & Streaming. Themes include Video Streaming, and Music Streaming. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -31523% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 2471x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.2% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -11895%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -11895% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
Valuation, Metrics & Events
STEX Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
1. Streamex underwent a significant rebranding and strategic pivot, changing its name from BioSig Technologies, Inc. to Streamex Corp., effective September 12, 2025, following a merger with Streamex Exchange Corporation. This marked a shift in focus to real-world asset (RWA) tokenization, particularly integrating the gold and commodities market into blockchain technology, and aiming to provide institutional-grade infrastructure for on-chain asset management.
2. Streamex received formal approval from Nasdaq for the continued listing of its shares of common stock on the Nasdaq Capital Market on October 30, 2025. This approval addressed concerns regarding its listing status and provided stability for investors.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STEX Return | - | - | - | - | - | - | |
| Peers Return | 52% | 3% | -11% | -6% | -18% | 41% | 52% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| STEX Win Rate | - | - | - | - | - | 0% | |
| Peers Win Rate | 50% | 42% | 40% | 35% | 31% | 53% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| STEX Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -31% | -15% | -31% | -31% | -27% | -13% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: A, ATEC, CERS, AVRT, BLLN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
STEX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1100 days | 1480 days |
Compare to
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| With Streamex Stock Sliding, Have You Assessed The Risk? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to STEX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Streamex
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.23 |
| Mkt Cap | 1.8 |
| Rev LTM | 464 |
| Op Inc LTM | -11 |
| FCF LTM | -2 |
| FCF 3Y Avg | -15 |
| CFO LTM | 19 |
| CFO 3Y Avg | -13 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 20.1% |
| Rev Chg 3Y Avg | 4.6% |
| Rev Chg Q | 12.3% |
| QoQ Delta Rev Chg LTM | 3.0% |
| Op Mgn LTM | -7.4% |
| Op Mgn 3Y Avg | -16.8% |
| QoQ Delta Op Mgn LTM | 2.6% |
| CFO/Rev LTM | 3.3% |
| CFO/Rev 3Y Avg | -7.6% |
| FCF/Rev LTM | -0.2% |
| FCF/Rev 3Y Avg | -15.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.8 |
| P/S | 4.0 |
| P/EBIT | -13.2 |
| P/E | -11.9 |
| P/CFO | 42.6 |
| Total Yield | -6.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -5.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.6% |
| 3M Rtn | 33.5% |
| 6M Rtn | 38.2% |
| 12M Rtn | 12.4% |
| 3Y Rtn | -2.0% |
| 1M Excs Rtn | 6.6% |
| 3M Excs Rtn | 22.9% |
| 6M Excs Rtn | 23.5% |
| 12M Excs Rtn | -4.5% |
| 3Y Excs Rtn | -72.6% |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12312024 | 4152025 | 10-K 12/31/2024 |
| 9302024 | 11142024 | 10-Q 9/30/2024 |
| 6302024 | 8142024 | 10-Q 6/30/2024 |
| 3312024 | 5202024 | 10-Q 3/31/2024 |
| 12312023 | 4162024 | 10-K 12/31/2023 |
| 9302023 | 11142023 | 10-Q 9/30/2023 |
| 6302023 | 8142023 | 10-Q 6/30/2023 |
| 3312023 | 5152023 | 10-Q 3/31/2023 |
| 12312022 | 3312023 | 10-K 12/31/2022 |
| 9302022 | 11142022 | 10-Q 9/30/2022 |
| 6302022 | 8152022 | 10-Q 6/30/2022 |
| 3312022 | 5162022 | 10-Q 3/31/2022 |
| 12312021 | 3312022 | 10-K 12/31/2021 |
| 9302021 | 11152021 | 10-Q 9/30/2021 |
| 6302021 | 8112021 | 10-Q 6/30/2021 |
| 3312021 | 5172021 | 10-Q 3/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |